1
|
Krause N, Mengwasser J, Phithak E, Beato F, Appis M, Milford EL, Pratschke J, Sauer I, Kuehl A, Vogel A, Goodyear M, Hammerich L, Tacke F, Haas JF, Müller T, Utku N. Immune Regulatory 1 Cells: A Novel and Potent Subset of Human T Regulatory Cells. Front Immunol 2022; 12:790775. [PMID: 35222353 PMCID: PMC8867398 DOI: 10.3389/fimmu.2021.790775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2021] [Accepted: 12/22/2021] [Indexed: 11/23/2022] Open
Abstract
A subset of T regulatory cells (Tregs), identified by TIRC7 (T cell immune response cDNA 7) expression is designated as Immune Regulatory 1 Cells (IR1 cells). TIRC7 is an immune checkpoint inhibitor, co-localized with the T- cell receptor, HLA-DR and CTLA-4 during T-cell activation, which delivers regulatory signals via binding to its ligand, HLA-DR α2 domain. IR1 cells express FOXP3, and multiple other markers associated with immune suppression. They constitute as much as 10% of Tregs. IR1 cells strongly inhibit proliferation in mixed lymphocyte reactions, where they express high levels of IL-10. Ex vivo expansion of Tregs over 2 weeks in the presence of an agonist TIRC7 antibody disproportionately expands the IR1 Treg subset, while maintaining high expression of suppressive markers including CD39, IL-10, LAP and GARP. Ex vivo expanded IR1 cells are a potent, homogeneous, stable set of suppressor Tregs with the potential to modulate immune dysregulation. The characteristics of IR1 cells suggest a therapeutic advantage over polyclonal Tregs for therapeutic interventions. Early restoration of immune homeostasis using IR1 cells has the potential to fundamentally alter the natural history of conditions characterized by abnormalities in the T regulatory cell compartment.
Collapse
Affiliation(s)
- Nicolas Krause
- Institute for Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.,Department of Hepatology and Gastroenterology, Universitätsmedizin Berlin, Berlin, Germany
| | - Jörg Mengwasser
- Department of Surgery, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Elpida Phithak
- Institute for Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.,Department of Hepatology and Gastroenterology, Universitätsmedizin Berlin, Berlin, Germany
| | - Francisca Beato
- Department of Gastroenterology, Moffit Cancer Center, Tampa, FL, United States
| | - Marc Appis
- Department of Biochemistry, Freie Universität, Berlin, Germany
| | - Edgar Louis Milford
- Department of Medicine, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
| | - Johan Pratschke
- Department of Surgery, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Igor Sauer
- Department of Surgery, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Anja Kuehl
- Department of Hepatology and Gastroenterology, Universitätsmedizin Berlin, Berlin, Germany
| | - Arndt Vogel
- Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
| | - Michael Goodyear
- Department of Medicine, Dalhousie University, Halifax, NS, Canada
| | - Linda Hammerich
- Department of Hepatology and Gastroenterology, Charite, Berlin, Germany
| | - Frank Tacke
- Department of Hepatology and Gastroenterology, Charite, Berlin, Germany
| | - Johanna Faith Haas
- Institute for Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Tobias Müller
- Department of Hepatology and Gastroenterology, Universitätsmedizin Berlin, Berlin, Germany
| | - Nalan Utku
- Institute for Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.,Sachs Incubator for Translational Medicine, Sächsische Inkubator für Klinische Translation (SIKT), University of Leipzig, Leipzig, Germany
| |
Collapse
|